NCT03123029

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Trial Health

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 18, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 21, 2017

Completed
Last Updated

January 30, 2026

Status Verified

April 1, 2025

First QC Date

April 18, 2017

Last Update Submit

January 29, 2026

Conditions

Chronic Lymphocytic Leukemia (CLL)Multiple MyelomaAcute Myeloid Leukemia (AML)Non-Hodgkin's LymphomaAcute Lymphoblastic Leukemia (ALL)AmyloidosisPlasma Cell Leukemia

Keywords

Expanded AccessPre-approval AccessCompassionate UseSpecial Access ProgramNamed Patient BasisSpecial Access Scheme

Interventions

VenetoclaxDRUG

Venetoclax will be administered orally.

Also known as: ABT-199, GDC-0199

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may not qualify if:

  • There are other suitable treatment options.
  • The participant qualifies for ongoing clinical trials.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Leukemia, Lymphocytic, Chronic, B-CellMultiple MyelomaLeukemia, Myeloid, AcuteLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaAmyloidosisLeukemia, Plasma Cell

Interventions

venetoclax

Condition Hierarchy (Ancestors)

Leukemia, B-CellLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsNeoplasms, Plasma CellHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHemorrhagic DisordersLeukemia, MyeloidLymphomaProteostasis DeficienciesMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • ABBVIE INC.

    AbbVie

    STUDY DIRECTOR

Central Study Contacts

ABBVIE CALL CENTER

CONTACT

844-663-3742abbvieclinicaltrials@abbvie.com

Study Design

Study Type
expanded access
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 18, 2017

First Posted

April 21, 2017

Last Updated

January 30, 2026

Record last verified: 2025-04